Arsenal Biosciences, Inc. | LinkedIn (original) (raw)

About us

ArsenalBiosciences, Inc., is a clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR-enabled genome editing, integrated circuits incorporating logic gates for improved tumor targeting, and therapeutic enhancements enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. Our team is engineering living medicines to attack cancer’s inherent multi-faceted nature and bring dramatic improvements to the lives of patients.

Industry

Biotechnology Research

Company size

201-500 employees

Headquarters

South San Francisco , CA

Type

Privately Held

Founded

2019

Specialties

Biotechnology, technology, artificial intelligence, cancer, immunology, cell therapy, and machine learning

Locations

Employees at Arsenal Biosciences, Inc.

Updates

Our greatest asset at ArsenalBio is our people. We’re honored to recognize our 2024 Mission Award recipients, who exemplify our core values and have made outstanding contributions toward achieving our goal of defeating cancer. Congratulations to Randy J. Reyes, J.D., Corporate Counsel II, and Michelle Tan, Senior Scientist I. Learn more about our team and open positions: https://bit.ly/3EgTl12
We’re excited to share that Bristol Myers Squibb has exercised its exclusive license option for our AB-4000 series as part of our multi-program collaboration to develop next-generation T cell therapies for solid tumors. This milestone demonstrates confidence in our programmable cell therapy platform and marks a key step toward advancing innovative solutions for patients battling solid tumor cancers. The AB-4000 series leverages ArsenalBio’s proprietary biological toolkit designed to overcome the challenges of addressing solid tumors, including targeting specificity and a suppressive tumor microenvironment. Thank you to the teams at ArsenalBio and Bristol Myers Squibb for their hard work and collaboration. Together, we’re pushing the boundaries of what’s possible in cancer treatment. Learn more via our latest press release. https://bit.ly/4h3hg2w
What a year! We’re reflecting on what we achieved in 2024 and our progress toward developing cell therapies for solid tumors. We’re proud of our incredible team that has made it all possible. Interested in joining our journey to defeat cancer? We’re hiring! Check out our open positions at https://bit.ly/4h8L8dz
Our CEO, Ken Drazan, M.D., will present at the J.P. Morgan Healthcare Conference on Monday, Jan. 13 at 4pm PT. He'll discuss our progress in developing cell therapies for solid tumors and the strides we’re making toward defeating cancer. #JPM2025 https://bit.ly/4gZhWFV
This week, we were at the 6th Annual Cell Therapy Analytical Development Summit in Boston. Thanks to our ArsenalBio scientists for sharing their insights on automation and cell therapy development with the scientific community. [photo: Jose Pena, Ph.D., Lindsay Rios, Haixia Wang, Ph.D., and Wendy N., Ph.D.]
Hear from our CEO Ken Drazan about Arsenal’s bright future and how we believe our industry-leading platform enables the discovery and development of next-generation medicines. Check out this Nasdaq Live from MarketSite video: https://bit.ly/4fhpL8X

Join now to see what you are missing

Join now